[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"labor-induction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:labor-induction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,72,102,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100613555","phase-2-pain-control-for-cervical-ripening-balloon-100613555",false,"NCT07268118","Pain Control for Cervical Ripening Balloon","Randomized Control Trial for Pain Control With Topical Lidocaine for Cervical Ripening Balloon Placement","Inclusion Criteria:\n\n* Age ≥18 years\n* Gestational age ≥37 weeks\n* Viable pregnancy\n* Intact membranes\n* English speaking\n* Interested in cervical ripening balloon placement\n* Able to provide consent\n\nExclusion Criteria:\n\n* Allergy or sensitivity to lidocaine\n* Patients that already have neuraxial anesthesia (i.e. spinal, epidural, combined spinal\u002Fepidural)\n* Known uterine or cervical anomalies","FEMALE","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","No standard of care exists for pain management during cervical ripening balloon placement. The purpose of this study is to evaluate if vaginal topical lidocaine reduces pain related to cervical ripening balloon placement during induction of labor.",[26],"Labor Induction",[28,29],"cervical ripening","cervical balloon","NOT_YET_RECRUITING","2026-03-03",{"date":33,"type":34},"2026-03-05","ACTUAL",{"date":36,"type":20},"2026-04",{"date":38,"type":20},"2027-06",{"name":40,"class":41},"Beth Israel Deaconess Medical Center","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100605873","the-effect-of-reflexology-on-time-to-delivery-during-induction-of-labor-100605873","NCT07168187","The Effect of Reflexology on Time to Delivery During Induction of Labor","The Effect of Reflexology Treatment on Maternal Anxiety During Induction of Labor With an Extra-amniotic Balloon","Inclusion Criteria:\n\n* Age of ≥18 years\n* Gestational age of \\>37 weeks\n* Vertex presentation\n* Intact membranes\n* Station of the fetus's head \\\u003C S-4\n* Bishop score of \\\u003C6.\n\nExclusion Criteria:\n\n* Patients who had undergone a previous cesarean delivery\n* Patients with a contraindication for vaginal delivery\n* Patients with a known fetal malformation patients undergoing termination of pregnancy.",true,{"count":51,"type":20},84,[53],"NA","This prospective, randomized controlled trial evaluates the effect of reflexology on maternal anxiety, labor duration, and pain in women undergoing labor induction with an extra-amniotic balloon (EAB). Eligible participants are women with a singleton, term pregnancy, cephalic presentation, intact membranes, and a Bishop score \\\u003C6, without prior cesarean delivery or contraindications to vaginal delivery.\n\nParticipants will be randomized to two groups: an intervention group receiving reflexology by a certified practitioner following EAB placement, and a control group receiving standard care. Maternal anxiety will be assessed using the State-Trait Anxiety Inventory (STAI) before and after the intervention. Labor duration and pain scores will also be recorded.\n\nThe study plans to enroll 84 participants over two years. Reflexology is a safe, non-invasive complementary therapy, and this study aims to determine whether it provides measurable benefits during labor induction.",[56,26,57],"Reflexology","Extra Amniotic Balloon",[59,60,61],"induction to delivery time","labor induction","maternal anxiety","2025-12-02",{"date":64,"type":34},"2025-12-10",{"date":66,"type":20},"2025-12-30",{"date":68,"type":20},"2026-08-01",{"name":70,"class":71},"Wolfson Medical Center","OTHER_GOV",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100560717","phase-4-calcium-carbonate-to-augment-labor-contractions-100560717","NCT06580782","Calcium Carbonate to Augment Labor Contractions","CALC","Inclusion Criteria:\n\n* 18 years or older\n* Nulliparas (no prior pregnancy lasting 20 weeks or greater of gestation)\n* Gestational age above 36 weeks, at enrollment\n* Present for induction or augmentation of labor inclusive of medical indication, elective induction at greater than 39 weeks' gestation, trial of labor after cesarean\n* Singleton gestation (a multiple gestation reduced to a singleton, either spontaneously or therapeutically, before 14 0\u002F7 weeks of gestation is acceptable)\n* Ability to give informed consent\n* Planned to undergo initiation of oxytocin infusion by their maternity care provider\n\nExclusion Criteria:\n\n* Unable to understand or read English\n* Presence of tachysystole (defined as more than 5 contractions in 10 minutes averaged over 30 minutes), recurrent variable or late fetal decelerations, and bradycardia in the prior 30 minutes before enrollment\n* Non-vertex presenting fetus at enrollment\n* Planned for cesarean delivery or contraindication to labor by institutional policy (e.g., placenta previa, vasa previa, active genital herpes infection, previous transmural myomectomy)\n* Multi-fetal gestation (twins, triplets, and higher order multiples)\n* Known contraindication to taking calcium carbonate including renal calculus, high urine calcium levels, elevated serum calcium, low serum phosphate, achlorhydria, or suspected digoxin toxicity.\n* Deliveries with fetal chronic and\u002For pregnancy-related conditions, IUFD (Intra Uterine Fetal Death) or premature \\< 36 weeks of gestation.\n* Major fetal anomaly suspected prenatally (defined as a fetal anomaly with anticipated neonatal intensive care unit admission)\n* Suspected alloimmunization (given the increased likelihood for anticipated neonatal intensive care unit admission)\n* Known severe fetal growth restriction (estimated fetal weight \\<3rd percentile) or abnormal umbilical artery Doppler studies (given the increased likelihood for anticipated neonatal intensive care unit admission)\n* Participation in another interventional study that influences management of labor and delivery or perinatal morbidity or mortality\n* Known allergic reactions to synthetic oxytocin intravenous solution or to Calcium Carbonate\n* Significantly impaired consciousness or executive function (e.g., intubated or sedated)\n* Patients treated with calcium channel blockers such as nifedipine or magnesium.\n* Chronic renal failure and hyperphosphatemia.\n* Inability to tolerate oral intake (i.e., nausea\u002Fvomiting)",{"count":80,"type":20},60,[82],"PHASE4","The investigators think that calcium carbonate can act as an assistive medication to improve contractions during labor.",[85,26,86],"Labor Dystocia","Labor Augmentation",[88,89,86,90,60],"Labor","Pregnancy","Calcium Carbonate","RECRUITING","2025-10-21",{"date":94,"type":34},"2025-10-23",{"date":96,"type":34},"2024-11-18",{"date":98,"type":20},"2025-12",{"name":100,"class":41},"Weill Medical College of Cornell University",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":101},"100601343","early-phase-1-effect-of-dexamethasone-on-labour-induction-in-term-pregnancies-100601343","NCT07109258","Effect of Dexamethasone on Labour Induction in Term Pregnancies","Inclusion Criteria:\n\n* Age \\> 18 years.\n* Nulliparous.\n* Vertex presentation.\n* Singleton pregnancy.\n* Gestational age ≥ 39 weeks according to a reliable date for the last menstrual period or a first-trimester ultrasound evaluation.\n* No contraindication for vaginal delivery.\n\nExclusion Criteria:\n\n* Indication for cesarean section e. g. Placenta previa, intrauterine growth retardation, non-vertex presentation and previous cesarean section.\n* Maternal medical disorders as diabetes mellitus and severe pre-eclampsia.\n* Preterm labour and preterm rupture of membranes.\n* Gestational age \\\u003C39 weeks of gestation.\n* Fetal macrosomia \\> 4kg (estimated by u\u002Fs).",{"count":109,"type":20},150,[111],"EARLY_PHASE1","The aim of the study is to assess the effect of dexamethasone on labour induction in term pregnancies.\n\nPrimary outcome:\n\nThe interval between initiation of induction and beginning of the active phase of labour.\n\nSecondary outcomes:\n\n* Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation).\n* Duration of second stage of labour\n* Mode of delivery.\n* Fetal outcome.\n\nGroup A:\n\nWill receive one dose of IM dexamethasone sodium phosphate 8 mg (2 mL).\n\nGroup B:\n\nWill receive vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.\n\nGroup C:\n\nWill receive one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.",[26],[26,115,116,117],"Dexamethasone","Misoprostol","Term pregnancies","2025-07-31",{"date":120,"type":34},"2025-08-07",{"date":122,"type":34},"2025-05-01",{"date":124,"type":20},"2025-09-15",{"name":126,"class":41},"Cairo University",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":144,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":101},"100554697","pain-management-with-virtual-reality-hypnosis-100554697","NCT06502457","Pain Management With Virtual Reality Hypnosis","Pain Management With Virtual Reality Hypnosis in Parturients in the Latency or Cervical Ripening Phase","PreVR","Inclusion Criteria:\n\n* Parturient over 18\n* Parturient who speaks and understands French\n* Parturient hospitalised prior to labour\n* Membranes intact or ruptured\n* Spontaneous or induced labour\n* Parturient in latency phase\n* Term ≥ 37SA\n* END \\> 3\n* Parturient requiring active pain management (medicinal or non-medicinal)\n* Low-risk pregnancy\n\nExclusion Criteria:\n\n* Parturient under legal protection\n* Parturient with a hearing impairment\n* Parturient with visual impairment\n* Parturient with epilepsy\n* Parturient with psychiatric problems\n* Pathological pregnancy\n* Parturient with chronic pain\n* Parturient with addiction-related disorders\n* Parturient allergic to paracetamol\n* Parturient allergic to phloroglucinol\n* Parturient allergic to codeine\n* Parturient allergic to nalbuphine\n* Parturient allergic to orozamudol",{"count":136,"type":20},142,[53],"The latency phase corresponds to the first phase of the first stage of labour, during which the parturient feels regular, rhythmic uterine contractions that are often painful, with or without changes of the cervix. This phase lasts an average of 8 hours for primiparous women, compared with 5 hours for multiparous women, and can last up to twenty hours in total.\n\nCervical ripening corresponds to the medical induction of regular, painful uterine contractions in order to obtain a favourable cervix for the induction of labour. Cervical ripening is carried out either medically (oral or local prostaglandins) or mechanically (double balloon dilatation) and accounts for 69.2% of labour inductions, which in turn account for 25.8% of births.\n\nAt Amiens-Picardie University Hospital, this maturation stage can last from a few hours to 2 days, depending on the service protocol.\n\nWhat these two stages of childbirth have in common is that they are both painful, with very few analgesic drugs available that can be used without side-effects on the foetus during pregnancy.\n\nIn recent years, there has also been a growing demand from parturients for the use of non-medicinal therapies.\n\nIt therefore seems essential to provide parturients with as many effective non-drug methods as possible to manage their pain properly.\n\nIf virtual reality hypnosis sessions prove to be effective, they will provide better pain management for women in labour, reduce the use of morphine derivatives (with their attendant side-effects, particularly on the foetus), and above all meet the growing demand from women in labour for the most physiological possible support during childbirth.",[140,141,142,26,143],"Hypnosis","Labor Pain","Virtual Reality","Latent Period",[145,146,147,60,148],"hypnosis","labor pain","virtual reality","latent period","2025-05-21",{"date":151,"type":34},"2025-05-25",{"date":153,"type":34},"2024-07-09",{"date":155,"type":20},"2025-08",{"name":157,"class":41},"Centre Hospitalier Universitaire, Amiens"]